AveXis, Inc. (NASDAQ:AVXS) VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the transaction, the vice president now directly owns 7,000 shares in the company, valued at approximately $661,360. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of AveXis, Inc. (NASDAQ AVXS) traded down $0.34 during trading hours on Tuesday, hitting $93.50. 350,535 shares of the company’s stock traded hands, compared to its average volume of 426,264. AveXis, Inc. has a 12 month low of $44.68 and a 12 month high of $108.27.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the business posted ($0.87) EPS. equities research analysts forecast that AveXis, Inc. will post -6.23 EPS for the current fiscal year.
AVXS has been the topic of several research analyst reports. Barclays initiated coverage on shares of AveXis in a research report on Wednesday, September 6th. They set an “overweight” rating and a $124.00 price target on the stock. Nomura initiated coverage on shares of AveXis in a research note on Monday, August 28th. They set a “reduce” rating and a $52.00 price objective on the stock. Zacks Investment Research upgraded shares of AveXis from a “hold” rating to a “buy” rating and set a $112.00 price objective on the stock in a research note on Tuesday, October 24th. Instinet initiated coverage on shares of AveXis in a research note on Tuesday, August 29th. They set a “reduce” rating and a $52.00 price objective on the stock. Finally, Bank of America dropped their price objective on shares of AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $110.67.
COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/05/andrew-f-knudten-sells-2000-shares-of-avexis-inc-avxs-stock.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
What are top analysts saying about AveXis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AveXis Inc. and related companies.